Desktop Health Announces First Patients Treated With FDA-Cleared CMFlex – An Off-The-Shelf 3D Printed Synthetic Bone Graft Product Pioneered By Dimension Inx On The 3D-Bioplotter






  • Chicago-based Dimension Inx, a regenerative therapeutics company, has now had its innovative CMFlex material implanted in multiple patients
  • CMFlex is an off-the-shelf, customizable bone graft material indicated for maxillofacial, mandibular, and dental bone defects
  • The first 3D printed regenerative bone graft product cleared by the FDA, CMFlex has now been used in two patient jaw surgeries, an upper and lower, and several dental socket preservation cases
  • CMFlex eliminates the need for doctors to invasively harvest bone from another area of a patient's body and shape it into a desired anatomy for a bone graft
  • Dimension Inx developed and manufactures CMFlex on the Desktop Health 3D-Bioplotter Manufacturing Series model
  • The 3D-Bioplotter has now been used for separate in-patient applications in Germany and the United States, as bioprinting applications in development for years begin advancing to the first in-patient applications
  • A video showcasing the work done by Dimension Inx on the 3D-Bioplotter is now available at

Desktop Health – the trusted production-grade medical 3D printing brand of Desktop Metal, Inc. (NYSE:DM) – today announced the first patients have been treated with CMFlex™, an off-the-shelf 3D printed synthetic bone graft product developed and manufactured by Chicago-based Dimension Inx on the 3D-Bioplotter®.

This press release features multimedia. View the full release here:

CMFlex™ was co-invented by Dimension Inx co-founders, Dr. Ramille Shah, CSO, Head of R&D, (pictured right) and Dr. Adam Jakus, CTO, Head of Technology Strategy, (pictured left). The duo have been developing the material and product since 2009 on the Desktop Health 3D-Bioplotter®. (Photo: Business Wire)

Founded in 2017, Dimension Inx is a regenerative therapeutics company that designs, develops, and manufactures therapeutic products to restore tissue and organ function. The company owns four Desktop Health 3D-Bioplotters – two used for R&D and two used for manufacturing their commercial CMFlex product.

Dimension Inx received FDA clearance of CMFlex in December of 2022. CMFlex is currently available to a limited number of key surgeons with a broader release to follow later in 2024.

The first jaw cases were performed by Dr. Derek Steinbacher, Director of West River Surgery Center (Guilford, CT ), Former Professor Plastic surgery and Chief of Oral and Maxillofacial surgery at Yale New Haven Health, and Dr. Brian Farrell, DDS, MD, of the Carolinas Center for Oral & Facial Surgery (Charlotte, NC). Procedures performed included a mandibular angle augmentation (surgery of the lower jaw) and maxillary segmental osteotomy (surgery of the upper jaw).

CMFlex has also been used in dental socket preservation surgeries for future dental implant placement by Dr. Robert Bosack, DDS, Oral, Maxillofacial & Dental Implant Surgery (Orland Park, IL).

"These first cases are not only indicative of a new generation of biomaterials, but also highlight our technology platform's unique capability to rapidly create biomaterials that direct cell behavior to restore tissue and organ function. It is a proud moment for us to be able to demonstrate the value of therapeutics derived from integrating novel biomaterial design and 3D-printing approaches," said Dr. Adam Jakus, CTO, Head of Technology Strategy, and Dimension Inx co-founder.

Dr. Ramille Shah, CSO, Head of R&D, and co-founder of Dimension Inx, added, "We're excited by the interest we've already received from surgeons who recognize the importance of a ready-to-use solution with great handling characteristics and the ability to cut and shape the graft to match the defect site."

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via